Trials / Active Not Recruiting
Active Not RecruitingNCT06335173
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 542 (actual)
- Sponsor
- Acumen Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sabirnetug | Intravenous sabirnetug |
| DRUG | Placebo | Intravenous Placebo |
Timeline
- Start date
- 2024-02-29
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2024-03-28
- Last updated
- 2025-10-27
Locations
68 sites across 5 countries: United States, Canada, Germany, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06335173. Inclusion in this directory is not an endorsement.